Inventor · disambiguated record
Revati Shreeniwas
Also filed as: SHREENIWAS REVATI
7 granted patents·4 pending applications·10 citations·filing 2013–2025
78Inventor score
Top patents by PatentIndex Score
11 records- 0193US10912778B2Methods for treatment of pulmonary hypertensionRESPIRA THERAPEUTICS INC·Filed 2017·Granted Feb 9, 2021·10 cites·17 claims
- 0283US12364701B2PDE5 inhibitor powder formulations and methods relating theretoRESPIRA THERAPEUTICS INC·Filed 2024·Granted Jul 22, 2025·0 cites·33 claims
- 0382US2025332171A1Pde5 inhibitor powder formulations and methods relating theretoRESPIRA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0479US12263174B2Methods and compositions for treatment of pulmonary hypertension and other lung disordersRESPIRA THERAPEUTICS INC·Filed 2022·Granted Apr 1, 2025·0 cites·19 claims
- 0577US11806314B2PDE5 inhibitor powder formulations and methods relating theretoRESPIRA THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·0 cites·37 claims
- 0677US11491161B2Methods and compositions for treatment of pulmonary hypertension and other lung disordersRESPIRA THERAPEUTICS INC·Filed 2021·Granted Nov 8, 2022·0 cites·30 claims
- 0774US2025195531A1Methods and compositions for treatment of pulmonary hypertension and other lung disordersRESPIRA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0873US11911390B2PDE5 inhibitor powder formulations and methods relating theretoRESPIRA THERAPEUTICS INC·Filed 2021·Granted Feb 27, 2024·0 cites·11 claims
- 0973US11491160B2Methods and compositions for treatment of pulmonary hypertension and other lung disordersRESPIRA THERAPEUTICS INC·Filed 2021·Granted Nov 8, 2022·0 cites·20 claims
- 1070US2016317542A1Pde5 inhibitor powder formulations and methods relating theretoRESPIRA THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 1140US2014057918A1Methods of Use for Monomethyl Fumarate and Prodrugs ThereofXENOPORT INC·Filed 2013·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Revati Shreeniwas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →